Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.

Products will arrive in a lyophilized (powder) form for maximum stability